Paper39600709
Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.
Santerre JP and 4 others. Front Immunol, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment. Papers, record 39600709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39600709
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Breast Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Biocompatible Materials | Major topic |
| Humans | |
| Female | |
| Animals | |
| Nanoparticles |
Source PubMed
References182
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38141488 | Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). | Lung Cancer | 2024 | https://conductscience.org/library/papers/38141488 | PubMed |
| 2 | 25345674 | The immune checkpoint inhibitors: where are we now? | Nat Rev Drug Discov | 2014 | https://conductscience.org/library/papers/25345674 | PubMed |
| 3 | 34551052 | DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy. | J Mater Chem B | 2021 | https://conductscience.org/library/papers/34551052 | PubMed |
| 4 | 33256070 | Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33256070 | PubMed |
| 5 | 28487109 | CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer. | Biochem Biophys Res Commun | 2017 | https://conductscience.org/library/papers/28487109 | PubMed |
| 6 | 22788954 | Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. | Breast Cancer Res | 2012 | https://conductscience.org/library/papers/22788954 | PubMed |
| 7 | 24762078 | Dendritic cell-based vaccines: clinical applications in breast cancer. | Immunotherapy | 2014 | https://conductscience.org/library/papers/24762078 | PubMed |
| 8 | 40395757 | Antigen/adjuvant-free liposome induces adjuvant effects for enhancing cancer immunotherapy. | Exploration (Beijing) | 2025 | https://conductscience.org/library/papers/40395757 | PubMed |
| 9 | 36797782 | NK cells are never alone: crosstalk and communication in tumour microenvironments. | Mol Cancer | 2023 | https://conductscience.org/library/papers/36797782 | PubMed |
| 10 | 37496657 | The role of cancer-associated fibroblasts in breast cancer metastasis. | Front Oncol | 2023 | https://conductscience.org/library/papers/37496657 | PubMed |
| 11 | 30734283 | In search of definitions: Cancer-associated fibroblasts and their markers. | Int J Cancer | 2020 | https://conductscience.org/library/papers/30734283 | PubMed |
| 12 | 31670078 | Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. | Biomaterials | 2020 | https://conductscience.org/library/papers/31670078 | PubMed |
| 13 | 31022431 | Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. | J Control Release | 2019 | https://conductscience.org/library/papers/31022431 | PubMed |
| 14 | 36925703 | Biomimetic cell membrane-coated poly(lactic-co-glycolic acid) nanoparticles for biomedical applications. | Bioeng Transl Med | 2023 | https://conductscience.org/library/papers/36925703 | PubMed |
| 15 | 35647515 | A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy. | Mater Today Bio | 2022 | https://conductscience.org/library/papers/35647515 | PubMed |
| 16 | 27782834 | Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. | J Exp Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27782834 | PubMed |
| 17 | 34209703 | Macrophage Polarization States in the Tumor Microenvironment. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34209703 | PubMed |
| 18 | 32849585 | The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. | Front Immunol | 2020 | https://conductscience.org/library/papers/32849585 | PubMed |
| 19 | 33587080 | Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. | Nanoscale Horiz | 2021 | https://conductscience.org/library/papers/33587080 | PubMed |
| 20 | 30465162 | Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. | Cancer Metastasis Rev | 2018 | https://conductscience.org/library/papers/30465162 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42445830 | Breaking the Barrier of Tumor Hypoxia: Oxygen-Enhancing Nano Biomaterials in Cancer Therapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42445830 | PubMed |
| 41933234 | Emerging nanoimmunotherapeutic strategies for breast cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41933234 | PubMed |
| 41828419 | Autophagy Modulation in Cancer Immunotherapy, Emerging Molecular Targets and Drug Selection Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828419 | PubMed |
| 41258978 | Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential. | Ther Innov Regul Sci | 2026 | https://conductscience.org/library/papers/41258978 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39600709
GET https://conductscience.org/api/papers/v1/39600709/references?page=2